Navigation Links
Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:10/2/2009

demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the SPA agreement on a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. sec
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
(Date:8/18/2014)... 18, 2014 Global HIV Infection Drug ... announced by Reportstack. The rate of HIV infection and the ... declining note at a positive rate across the globe. It ... million in 2005 to 1.5 in 2013, with the rates ... such drastic changes in the infection rates has been the ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Nexavar Net Sales increase 107% over Second Quarter 2007, ... ONXX ) today reported its financial results,for the ... reported net income,of $4.5 million, or $0.08 per diluted ... net loss of $10.8 million, or $0.22 per diluted ...
... HILL, N.J., Aug. 5 TriMix Laboratories LLC ... American Pharmacy Solutions,as the exclusive pharmacy for prescription ... by doctors as a first line and secondary,treatment ... a licensed compounding pharmacy which makes TriMix gel(TM) ...
... TEL AVIV, Israel, BADAJOZ, Spain and SINGAPORE, August 5 ... been appointed as the,new Chief Executive Officer effective July ... 20 years of experience in sales,marketing and senior management ... VP of Marketing and Sales at UltraShape Ltd., a ...
Cached Biology Technology:Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10TriMix Laboratories Announces New Partnership With American Pharmacy Solutions 2TriMix Laboratories Announces New Partnership With American Pharmacy Solutions 3Pollogen Announces Appointment of Ms. Yfat Scialom as Chief Executive Officer 2
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... University of Tbingen, Arizona State University, the Wellcome Trust ... Institute (Swiss TPH) isolated Mycobacterium pinnipedii from ... years old. The pathogen is a relative of the ... disease in humans today. These researchers assume that seals ... "The link to sea lions was unexpected" comments Sebastien ...
(Date:8/20/2014)... SILICON VALLEY, Calif., August 19, 2014 -- Bay Area ... to diagnose and simple to cure, applauds new research ... review journal Ticks and Tick-borne Diseases . ... in Northwest California are active throughout the year, making ... conducted by researchers at California Department of Public Health ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... sandpipers ( Calidris pusilla ) feeding during low tide ... Beauchamp, an ornithologist and research officer at the University ... the periphery remained alert and used short pecks to ... the group relaxed their vigilance and fed on a ...
... are the heart of the smaller, better electronics ... new materials, medical diagnostics and therapeutics, energy storage, ... have unintended consequences for human health and the ... and policy makers, the Virginia Tech Center for ...
... long lasting, possibly permanent, performance-enhancing effects, shows a study ... Physiology ., Previously, re-acquisition of muscle mass with ... has been attributed to motor learning. However, this new ... is a cellular ,memory mechanism, within muscle of brief ...
Cached Biology News:Bird buffet requires surveillance 2Nanomaterials database improved to help consumers, scientists track products 2Nanomaterials database improved to help consumers, scientists track products 3Nanomaterials database improved to help consumers, scientists track products 4
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... Designed for in vitro diagnostic assays, ... medical-grade polystyrene for uniform binding, high optical ... the Easy-Washproducts are part of the Certified ... performance to be within QA release specifications. ...
... StabilZyme SELECT Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a saline ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer is a diluent and stabilizer for ...
AC input: 230 V...
Biology Products: